Lipocine Inc. (LPCN): Price and Financial Metrics

Lipocine Inc. (LPCN): $3.81

0.09 (-2.31%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

LPCN Price/Volume Stats

Current price $3.81 52-week high $8.33
Prev. close $3.90 52-week low $2.31
Day low $3.80 Volume 9,000
Day high $3.98 Avg. volume 29,889
50-day MA $3.47 Dividend yield N/A
200-day MA $3.69 Market Cap 20.25M

LPCN Stock Price Chart Interactive Chart >

LPCN Stock Summary

  • For LPCN, its debt to operating expenses ratio is greater than that reported by just 0.22% of US equities we're observing.
  • Over the past twelve months, LPCN has reported earnings growth of -492.31%, putting it ahead of merely 2.61% of US stocks in our set.
  • Revenue growth over the past 12 months for LIPOCINE INC comes in at -118.49%, a number that bests merely 0.55% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to LPCN, based on their financial statements, market capitalization, and price volatility, are VYGR, HYLN, DRRX, PRTC, and GSIT.
  • LPCN's SEC filings can be seen here. And to visit LIPOCINE INC's official web site, go to www.lipocine.com.

LPCN Valuation Summary

  • In comparison to the median Healthcare stock, LPCN's price/sales ratio is 214.29% lower, now standing at -4.8.
  • Over the past 124 months, LPCN's price/earnings ratio has gone up 2057.9.

Below are key valuation metrics over time for LPCN.

Stock Date P/S P/B P/E EV/EBIT
LPCN 2023-12-29 -4.8 0.7 -0.9 -0.7
LPCN 2023-12-28 -4.9 0.7 -0.9 -0.7
LPCN 2023-12-27 -5.1 0.7 -1.0 -0.7
LPCN 2023-12-26 -5.1 0.7 -1.0 -0.7
LPCN 2023-12-22 -5.1 0.7 -1.0 -0.7
LPCN 2023-12-21 -5.1 0.7 -1.0 -0.7

LPCN Growth Metrics

    Its 2 year cash and equivalents growth rate is now at -71.53%.
  • Its 2 year price growth rate is now at 18.21%.
  • The 3 year cash and equivalents growth rate now stands at -56.64%.
LPCN's revenue has moved up $16,585,844 over the prior 15 months.

The table below shows LPCN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 16.58584 -1.135365 4.095298
2022-06-30 16.64084 -4.917978 3.423166
2022-03-31 16.14084 -4.234931 -0.754098
2021-12-31 16.14084 -4.411303 -0.634399
2021-09-30 0.054994 -17.08987 -17.7697
2021-06-30 0 -14.27264 -19.00166

LPCN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • LPCN has a Quality Grade of D, ranking ahead of 21.42% of graded US stocks.
  • LPCN's asset turnover comes in at 0 -- ranking 440th of 680 Pharmaceutical Products stocks.
  • ZTS, MDWD, and GERN are the stocks whose asset turnover ratios are most correlated with LPCN.

The table below shows LPCN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.000 NA -1.022
2021-03-31 0.000 NA -1.500
2020-12-31 0.000 NA -4.723
2020-09-30 0.000 NA -3.288
2020-06-30 0.008 1 -2.946
2020-03-31 0.008 1 -1.844

LPCN Price Target

For more insight on analysts targets of LPCN, see our LPCN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.75 Average Broker Recommendation 1.33 (Strong Buy)

Lipocine Inc. (LPCN) Company Bio


Lipocine develops pharmaceutical products using its oral drug delivery technology in the areas of men’s and women’s health, with a current focus being testosterone replacement. The company was founded in 1997 and is based in Salt Lake City, Utah.


LPCN Latest News Stream


Event/Time News Detail
Loading, please wait...

LPCN Latest Social Stream


Loading social stream, please wait...

View Full LPCN Social Stream

Latest LPCN News From Around the Web

Below are the latest news stories about LIPOCINE INC that investors may wish to consider to help them evaluate LPCN as an investment opportunity.

Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that results of its Phase 2 study evaluating LPCN 1148 are being presented at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, taking place in Boston MA. The results are featured in a late-breaking oral presentation and e-poster by Dr. Arun Sanyal, MD, Director, Stravitz-Sanyal Institute for Liver Disease and Metabolic He

Yahoo | November 13, 2023

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform to develop differentiated products, today announced financial results for the third quarter and nine months ended September 30, 2023, and provided a corporate update.

Yahoo | November 8, 2023

Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that an abstract on LPCN 1148 has been selected for a late breaking oral presentation at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, to take place in Boston MA, November 10 to 14, 2023.

Yahoo | November 1, 2023

Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform, today announced the completion of a meeting with the FDA and guidance for the appropriate acceptance criteria for the upcoming LPCN 1154 pivotal study.

Yahoo | October 26, 2023

Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that it will present and meet with investors at the H.C. Wainwright 7th Annual NASH Investor Conference, taking place virtually October 24, 2023.

Yahoo | October 23, 2023

Read More 'LPCN' Stories Here

LPCN Price Returns

1-mo -0.52%
3-mo 52.40%
6-mo -4.75%
1-year -47.93%
3-year -86.33%
5-year -86.82%
YTD 36.56%
2023 -58.74%
2022 -59.86%
2021 -27.13%
2020 253.34%
2019 -70.39%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!